Literature DB >> 19687246

Antifungal activity of micafungin in serum.

Jun Ishikawa1, Tetsuo Maeda, Itaru Matsumura, Masato Yasumi, Hidetoshi Ujiie, Hiroaki Masaie, Tsuyoshi Nakazawa, Nobuo Mochizuki, Satoshi Kishino, Yuzuru Kanakura.   

Abstract

We have evaluated the antifungal activity of micafungin in serum by using the disk diffusion method with serum-free and serum-added micafungin standard curves. Serum samples from micafungin-treated patients have been shown to exhibit adequate antifungal activity, which was in proportion to both the applied dose and the actual concentration of micafungin measured by high-performance liquid chromatography. The antifungal activity of micafungin in serum was also confirmed with the broth microdilution method.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19687246      PMCID： PMC2764204          DOI： 10.1128/AAC.01404-08

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

1.  Serum differentially alters the antifungal properties of echinocandin drugs.

Authors:  Padmaja Paderu; Guillermo Garcia-Effron; Sergey Balashov; Guillaume Delmas; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-04-09       Impact factor: 5.191

2.  Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders.

Authors:  Kazuo Tamura; Akio Urabe; Minoru Yoshida; Akihisa Kanamaru; Yoshihisa Kodera; Shinichiro Okamoto; Shigefumi Maesaki; Tohru Masaoka
Journal:  Leuk Lymphoma       Date:  2009-01

3.  Effects of serum on in vitro susceptibility testing of echinocandins.

Authors:  Zekaver Odabasi; Victor Paetznick; John H Rex; Luis Ostrosky-Zeichner
Journal:  Antimicrob Agents Chemother       Date:  2007-09-04       Impact factor: 5.191

4.  Linear pharmacokinetics of micafungin and its active metabolites in Japanese pediatric patients with fungal infections.

Authors:  Kenji Tabata; Masataka Katashima; Akio Kawamura; Yusuke Tanigawara; Keisuke Sunagawa
Journal:  Biol Pharm Bull       Date:  2006-08       Impact factor: 2.233

5.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

Authors:  S Ascioglu; J H Rex; B de Pauw; J E Bennett; J Bille; F Crokaert; D W Denning; J P Donnelly; J E Edwards; Z Erjavec; D Fiere; O Lortholary; J Maertens; J F Meis; T F Patterson; J Ritter; D Selleslag; P M Shah; D A Stevens; T J Walsh
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

6.  In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.

Authors:  S Tawara; F Ikeda; K Maki; Y Morishita; K Otomo; N Teratani; T Goto; M Tomishima; H Ohki; A Yamada; K Kawabata; H Takasugi; K Sakane; H Tanaka; F Matsumoto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

7.  Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds.

Authors:  Katsuyuki Maki; Satoru Matsumoto; Etsuko Watabe; Yumi Iguchi; Masaki Tomishima; Hidenori Ohki; Akira Yamada; Fumiaki Ikeda; Shuichi Tawara; Seitaro Mutoh
Journal:  Microbiol Immunol       Date:  2008-08       Impact factor: 1.955

8.  Influence of serum protein binding on the in vitro activity of anti-fungal agents.

Authors:  M Schäfer-Korting; H C Korting; W Rittler; W Obermüller
Journal:  Infection       Date:  1995 Sep-Oct       Impact factor: 3.553
  8 in total
  6 in total

1.  Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.

Authors:  Elisabetta Spreghini; Fiorenza Orlando; Maurizio Sanguinetti; Brunella Posteraro; Daniele Giannini; Esther Manso; Francesco Barchiesi
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

2.  Killing Activity of Micafungin Against Candida albicans, C. dubliniensis and Candida africana in the Presence of Human Serum.

Authors:  Renátó Kovács; Qasem Saleh; Aliz Bozó; Zoltán Tóth; Rudolf Gesztelyi; Tamás Kardos; Gábor Kardos; István Takacs; László Majoros
Journal:  Mycopathologia       Date:  2017-07-11       Impact factor: 2.574

3.  Amphotericin B- and voriconazole-echinocandin combinations against Aspergillus spp.: Effect of serum on inhibitory and fungicidal interactions.

Authors:  Antigoni Elefanti; Johan W Mouton; Paul E Verweij; Athanassios Tsakris; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

4.  Improved detection of Candida sp. fks hot spot mutants by using the method of the CLSI M27-A3 document with the addition of bovine serum albumin.

Authors:  Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

5.  Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum.

Authors:  Antigoni Elefanti; Johan W Mouton; Katerina Krompa; Rafal Al-Saigh; Paul E Verweij; Loukia Zerva; Joseph Meletiadis
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

6.  Comparison of in vitro and vivo efficacy of caspofungin against Candida parapsilosis, C. orthopsilosis, C. metapsilosis and C. albicans.

Authors:  Richárd Földi; Renátó Kovács; Rudolf Gesztelyi; Gábor Kardos; Réka Berényi; Béla Juhász; Judit Szilágyi; Julianna Mózes; László Majoros
Journal:  Mycopathologia       Date:  2012-05-08       Impact factor: 2.574
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.